J D Wilson|M Feldmann - JoVE Visualize

Showing results (381-390 of 853) with videos related to

Pageof 86

Sort By:

Immunology|April 1, 1985

Augmentation of cell-mediated responses in vitro by a monoclonal anti-helper factor antibodyR F James, G H Sunshine, S Edwards, et al.

Clinical and Experimental Rheumatology|November 1, 1994

Targeting TNF alpha for the therapy of rheumatoid arthritisR N Maini, M Elliott, F M Brennan, et al.

Clinical and Experimental Immunology|August 1, 1979

Selective production of human antigen specific helper factor from normal volunteers: implications for human Ir genesN J Zvaifler, M Feldmann, S Howie, et al.

Insect Molecular Biology|September 2, 1998

Two-dimensional gel analysis of midgut proteins of Anopheles stephensi lines with different susceptibility to Plasmodium falciparum infectionG I Prévot, C Laurent-Winter, A M Feldmann, et al.

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|April 1, 1997

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesisR N Maini, M Elliott, F M Brennan, et al.

Journal of Autoimmunity|June 1, 1989

Cytokine production in culture by cells isolated from the synovial membraneF M Brennan, D Chantry, A M Jackson, et al.

European Journal of Immunology|July 1, 1991

Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-betaM Turner, D Chantry, P Katsikis, et al.

Dalton Transactions (Cambridge, England : 2003)|June 28, 2013

A theoretical study on the ring expansion of NHCs by silanesKalon J Iversen, David J D Wilson, Jason L Dutton

Inorganic Chemistry|June 27, 2012

Are N-heterocyclic carbenes "better" ligands than phosphines in main group chemistry? A theoretical case study of ligand-stabilized E2 molecules, L-E-E-L (L = NHC, phosphine; E = C, Si, Ge, Sn, Pb, N, P, As, Sb, Bi)David J D Wilson, Shannon A Couchman, Jason L Dutton

Annals of the Rheumatic Diseases|December 1, 1999

The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?M Feldmann, J Bondeson, F M Brennan, et al.

Pageof 86

Showing results (381-390 of 853) with videos related to

Sort By:

Pageof 86

Immunology|April 1, 1985

Augmentation of cell-mediated responses in vitro by a monoclonal anti-helper factor antibodyR F James, G H Sunshine, S Edwards, et al.

Clinical and Experimental Rheumatology|November 1, 1994

Targeting TNF alpha for the therapy of rheumatoid arthritisR N Maini, M Elliott, F M Brennan, et al.

Clinical and Experimental Immunology|August 1, 1979

Selective production of human antigen specific helper factor from normal volunteers: implications for human Ir genesN J Zvaifler, M Feldmann, S Howie, et al.

Insect Molecular Biology|September 2, 1998

Two-dimensional gel analysis of midgut proteins of Anopheles stephensi lines with different susceptibility to Plasmodium falciparum infectionG I Prévot, C Laurent-Winter, A M Feldmann, et al.

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|April 1, 1997

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesisR N Maini, M Elliott, F M Brennan, et al.

Journal of Autoimmunity|June 1, 1989

Cytokine production in culture by cells isolated from the synovial membraneF M Brennan, D Chantry, A M Jackson, et al.

European Journal of Immunology|July 1, 1991

Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-betaM Turner, D Chantry, P Katsikis, et al.

Dalton Transactions (Cambridge, England : 2003)|June 28, 2013

A theoretical study on the ring expansion of NHCs by silanesKalon J Iversen, David J D Wilson, Jason L Dutton

Inorganic Chemistry|June 27, 2012

Are N-heterocyclic carbenes "better" ligands than phosphines in main group chemistry? A theoretical case study of ligand-stabilized E2 molecules, L-E-E-L (L = NHC, phosphine; E = C, Si, Ge, Sn, Pb, N, P, As, Sb, Bi)David J D Wilson, Shannon A Couchman, Jason L Dutton

Annals of the Rheumatic Diseases|December 1, 1999

The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?M Feldmann, J Bondeson, F M Brennan, et al.

Pageof 86